Termination of Material Agreement Form 8 K

Item 1.02Termination of a Material Definitive Agreement

As previously disclosed, on July 22, 2022, CervoMed Inc. (the "Company") entered into an At-The-Market Sales Agreement (the "Sales Agreement") with BTIG, LLC, as sales agent and/or principal (the "Agent"), pursuant to which the Company was entitled to sell up to an aggregate of $20,000,000 of shares of the Company's common stock, par value $0.001 (the "Shares"), from time to time through the Agent in "at-the-market offerings" as defined in Rule 415 of the Securities Act of 1933, as amended (the "ATM Offering").

On October 1, 2024, pursuant to and in accordance with Section 12(b) of the Sales Agreement, the Company notified the Agent that the Company is terminating the Sales Agreement, effective October 11, 2024. The Company is not subject to any termination penalties or other expenses related to the termination of the Sales Agreement and, prior to termination, no Shares were sold in the ATM Offering.

The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which was is filed as Exhibit 1.1 to the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on July 22, 2022.